New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 14, 2014
08:06 EDTKMDAKamada reports Q2 EPS (23c), consensus (2c)
Reports Q2 revenue $15.8M, consensus $17.17M. Reports adjusted net loss $7.4M, compared with adjusted net income of $2.7M for the same period in 2013.
News For KMDA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 6, 2015
09:17 EDTKMDAKamada to present reults from European Phase 2/3 study of inhaled AAT
Kamada will host a panel discussion titled, “New Treatment Prospects for AATD Patients: Results from a Phase 2/3 Inhaled AAT Trial,” which will be led by Key Opinion Leaders who specialize in treating patients with alpha-1 antitrypsin deficiency during the upcoming American Thoracic Society 2015 International Conference being held May 15-20, 2015 in Denver, Colorado. The panel discussion will take place on Tuesday, May 19, 2015 from noon to 2:00 pm Mountain Time at the Westin Denver Downtown. We are delighted to bring together this panel of renowned Key Opinion Leaders, who have a special interest and expertise in AATD to discuss the final results from our European Phase 2/3 clinical study of the company’s inhaled AAT therapy to treat AATD,” said David Tsur, co-founder and CEO of Kamada. “The recently reported final results from the study showed clinically and statistically significant improvements in spirometric measures of lung function, particularly in bronchial airflow measurements FEV1, FEV1% predicted and FEV1/SVC. These favorable results were even more evident when analyzing the overall treatment effect throughout the full year.
April 28, 2015
06:03 EDTKMDAKamada announces management changes including CEO and COO
Kamada announces executive management changes intended to strengthen the company’s leadership while benefiting from its accomplished executives and advancing its protein therapeutics platform. Under the changes, David Tsur, co-founder and CEO, will become Deputy Executive Chairman of the Board, a new position whereby he will maintain his strategic advisory role yet relinquish day-to-day management responsibilities. Leon Recanti will remain the Chairman of the Board. Amir London, the Company’s Senior Vice President of Business Development, will become CEO and Gil Efron, currently CFO, will take on the added role of Deputy CEO. The changes are expected to go into effect in July 2015. London has more than 20 years of senior management and international business development experience. Prior to joining Kamada in December 2013, he was COO of Fidelis Diagnostics, a U.S.-based provider of innovative in-office medical diagnostic services.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use